DOCSLIB.ORG

Us 2019 / 0127401 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Us 2019 / 0127401 A1 US 20190127401A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0127401 A1 ZHAO et al. (43 ) Pub . Date : May 2 , 2019 ( 54 ) CHARGED LINKERS AND THEIR USES FOR Publication Classification CONJUGATION (51 ) Int. Ci. CO7F 9 / 30 (2006 . 01 ) (71 ) Applicant : HANGZHOU DAC BIOTECH CO . , CO7F 9 /572 ( 2006 . 01 ) LTD ., Hangzhou ( CN ) C07F 9 /6558 ( 2006 .01 ) A61K 47/ 68 ( 2006 . 01 ) (72 ) Inventors : Robert Yongxin ZHAO , Hangzhou C07F 9 /6561 ( 2006 . 01 ) ( CN ) ; Xing LI, Hangzhou (CN ) ; CO7F 9 / 32 ( 2006 .01 ) Yuangyuang HUANG , Hangzhou A61K 38 /07 ( 2006 . 01 ) (CN ) ; Qingliang YANG , Hangzhou CO7F 9 /58 ( 2006 . 01) ( CN ) .) U . S . CI. CPC . C07F 9 / 301 ( 2013 .01 ) ; CO7F 9 / 58 ( 2013 .01 ) ; CO7F 9 /65583 ( 2013 .01 ) ; A61K (73 ) Assignee : HANGZHOU DAC BIOTECH CO ., 47/ 6817 ( 2017 .08 ) ; A61K 47 /6851 ( 2017 .08 ) ; LTD . , Hangzhou (CN ) A61K 47 /6811 ( 2017 .08 ) ; A61K 47 /6809 ( 2017 .08 ) ; A61K 47/ 6807 ( 2017 .08 ) ; A61K (21 ) Appl . No. : 16 / 228 , 437 47 /6803 (2017 .08 ) ; A61K 47 /6889 ( 2017 . 08 ) ; CO7F 9 /65616 (2013 .01 ) ; CO7F 9 /3211 ( 2013 . 01 ) ; CO7F 9 / 3217 ( 2013 .01 ) ; A61K ( 22 ) Filed : Dec. 20 , 2018 38 /07 ( 2013 . 01 ) ; C07F 9 / 302 ( 2013 . 01) ; C07F 9 / 6561 ( 2013 .01 ) ; C07F 9 /572 ( 2013 .01 ) Related U . S . Application Data (57 ) ABSTRACT (62 ) Division of application No . 15 / 118 , 726 , filed on Aug . Cell binding agent -drug conjugates comprising phosphinate 12 , 2016 , filed as application No . PCT/ CN2014 / based charged linkers and methods of using such linkers and 072769 on Feb . 28 , 2014 . conjugates are provided . Patent Application Publication May 2 , 2019 Sheet 1 of 22 US 2019 /0127401 A1 H - P - H HMDS C OSiMe3 2 COOEt MezSi . , BrBr ? NH * 120 °C, 2h | OSiMe, J 50 °C, 2h . 120 °C , 5h |Mezsio 42 % from 1 Brave CH (OEt ) ; BrenP 0 OH 140 °C OEt 5 HSAC Acs 1 ). IN NaOH DIPEA VET 2 ) , pH 7 Na OH OEt PySSPy , 85 % OH NHS/ EDC Drug - SH Drug HCI/ DMA N pH 4 ~ 7 Antibodies Drug or Proteins NA MAL j n = 1 - 20 Antibodies or Proteins I ' N SL hmAb OH e Qeven in g ehele11a omas 11 Fig . 1 . Patent Application Publication May 2 , 2019 Sheet 2 of 22 US 2019 / 0127401 A1 HSAC 1 ) . NaOH ACS . Et 2 ), pH 7 OH 4 DIPEA PySSPy , 85 % NHS /EDC Drug -SH 82 % pH 4 ~ 7 Drug Antibodies Drug - S. or Proteins fu mAh mesinin bir pa r ently Jnunder = 1 ~ 20 Fig. 2 . Et f 120 °C NaH / DMF then 5 , 6 OEt DMA 18 Drug - SH Drug Antibodies or Proteins S pH 4 ~ 7. 5 OH 19 pH 5 .5 ~ 8 .5 Drug mAb N4 OHHIJn = 1 - 20 20 Fig . 3 . Patent Application Publication May 2 , 2019 Sheet 3 of 22 US 2019 / 0127401 A1 HMDS I OSIMez 1 Br H - PH HPOSiMe3 1 a coo?t Mez Sio Br ONH , + 120 °C 1 Mez / 50 °C , 26 MezSio " 120 °C , 5h 1 2 43 % in 3 steps CH (OEt ) ; OEt minh OH cong140 °C ngÓEt mga HSAC Br 1 ) . NaOH DIPEA 2 ) , pH 7 OH 72 % from 4 ÓFt PySSPy, 85 % NHS/ EDC Drug - SH Drug 82 % ??? ( - ? pH? 4 -? 7 ?OH ? Antibodies or Proteins 2 .win in Inthe = more1 20 Fig . 4 . HMDS OSiMe3 H - P - H HP a cooEt | MezSio Br Br O?NH4+ 120 °C OSiMe3 50 °C , 2h TOEt 120 °C , 5h Mezsio 43 % in 3 steps when one or more thanOEt HSAC P 1 ). NaOH DIPEA ÁCS OEt 2 ), pH 7 T OH homewhere to PySSPy , 85 % ripulinkyOH 33 NHS/ EDC Drug -SH Drug S 82 % pH 4 ~ 7 OH 35 1 2 Fig 5 . Patent Application Publication May 2 , 2019 Sheet 4 of 22 US 2019 /0127401 A1 HMDS I ?? - ? HP OSiMe3 2 COOEE (MezSio Br Br ?NH + 120 °C | OSiMe31750°C , 2h Mezsio 120 °C , 5h 43 % in 3 steps CH (OEt ) ; Br OEt 140 °C Br OEt at the37 end 38 of the HSAC 1 ) . NaOH DIPEA OEt 2 ) , pH 7 S - OH PySSPy NHS /EDC Drug -SH Drug 83 % pH 4 7 So Antibodies Drug S . or Proteins ???? mAh * OHfententiae Jnr 1 - 20 Fig. 66 . X CH (OET ) ; oEt 140 °C VOET OH 37 OEt 38 OEt C2H30CSSK 1 ) . NaOH OEt SO C2H5OH 2 ), pH 7 N S- S OH bet 45 PySSPy 411 NHS/ EDC Drug - SH Drug ons83 % herseling og pH 4 - 7kontinuing Antibodies rug nu mAb or Proteins 44 In = 1 ~ 20 Fig . 7 . Patent Application Publication May 2 , 2019 Sheet 5 of 22 US 2019 / 0127401 A1 ÇO2Et H - P - H AIBN /MeOH ÇO Et ÓH CO2Et 80°C , 5h HP CO , Et H1 CCO Et 46 47 OH 48 HMDS Br - Bi CH (OET ) 120 °C , 9h 140 °C 49 OEt 50 HSAC ACS . 1 ) . NaOH DIPEA 2 ), pH 7 .5 Et 51 PySSPy OH 52 0 O NHS /EDC 0 Drug- SH Drug sr 82 % ? pH 4 - 7 's -Sriwi o Nog inn i en OH 54 Antibodies mAb or Proteins Nam Jn = 1 ~ 20 Fig . 8 . Patent Application Publication May 2 , 2019 Sheet 6 of 22 US 2019 /0127401 A1 CO2Et AIBN /MeOH ÇO2Et H - P - H HP HB OH CO2Et - 80 °C , 5h | CO, Et CO Et 1 46 OH 48 HMDS Br - brBr CH (OET ) 3 Br OEt 120 °C , 9h 140°C OEt 56 EtOCSSK 1 ) . NaOH OEt 2 ) , pH 7 . 5 OH InTfz / EtOH OEt 58 PySSPy OH 59 NHS / EDC Drug- SH Drugs 82 % pH 4 - 7 OH 61 Antibodies Dru or Proteins Normab OH n = 1 - 20 Fig 9 . EtOCSSK 1 ) . NaOH EtOH 2 ), pH 7 .5 mylimahora en verlinktenPySSPy OH 59 Drug -SH Drug Antibodies pH 4 ~ 7 OM or Proteins 1 61 Drug VAL [user findestensn = 1 - 20 Fig 10 . Patent Application Publication May 2 , 2019 Sheet 7 of 22 US 2019 /0127401 A1 Bn OH /DCC /DMAP H - P - H HMDS ( ., OSiMe3 | Br?cook int O -NH ,+ 120°C , 2h ! SiMe3 / 50 °C , 2h Ôu THF , RT , 16h 2 Hp BrBr Brno 120 °C , 5h got OBA 65 OBn 66 HSAC Acs 1 ). 5N HCI, 100°C 2 ) , pH 7 OH DIPEA OBn PySSPy , 85 % NHS/ EDC Drug -SH 82 % pH 4 - 7 Antibodies Drug S or Proteins ÓH NAn = 1 ~ 20 or : oynamaktan olimline 69 2 11 Fig . 11. Patent Application Publication May 2 , 2019 Sheet 8 of 22 US 2019 / 0127401 A1 I BnOH /DCC /DMAP PH HMDS HP OSiMe3 1 Brycod + 120°C , 2h O SIMez ) 50 °C , 2h THF, RT, 16h Br Br OBn 120 °C , 5h OBn a les66 est le 15 O 1 ) . 5N HCI, 100°C 2 ) , pH 7 NaH /DMF PySSPy , 85 % NHS / EDC Drug - SH Drug 82 % pH 4 - 7 eins or : Antibodies or Proteins INSHj n = 1 ~ 20 - Painting a 71 Drug -SH Drug pH 4 ~ 7 and| H the| n = 1 - 20 Fig . 12 . Patent Application Publication May 2 , 2019 Sheet 9 of 22 US 2019 / 0127401 A1 Quintocounter Jn = 1 - 20 Drug - - SSPy or DTT or TCEP Drug - SSPYNO2 pH 4 - 8 . 5 Jn = 1 - 20 YpH 5 - 8 .5 pH 5 - 8 . 5 / Drug Drug N 1 Jnr 1 - 20 11 presente ne DU 73 74 Fig . 13 . HMDS I I H - P - H cooEt MezSio . o Brio Br ONH + 120°C , 2h IHP .OSiMez :Mel ) 50 °C ,. 2h2h OEt Mezsio 3 120 °C , 5h m = 1 - 24 CH (OET ) OEt 3140 °C Et EtOCSSK Im OH 75 m OTt EtOH 1 ) . IN NaOH OEt 2) , pH 7 ' N OH OEt PySSPy , 85 % OH AtMatte 7 ?? NHS/ EDC N" S - S ' m = 1 ~ 24 82 % Im OH Fig . 14 . Patent Application Publication May 2 , 2019 Sheet 10 of 22 US 2019 / 0127401 A1 OH 4 OEt 5 87 Antibodies 3 or Proteins minimal things are comingOH Hj n = 1 ~ 20 pH 4 - 7 l Nan OHÀ Jn = 1 – 20 Fig . 15 . Patent Application Publication May 2 , 2019 Sheet 11 of 22 US 2019 / 0127401 A1 - H - - - - NaN3 IN NaOH Pd / C / H , DMF OEt OH CH3OH OEt 86 87 NHS /EDC HN OH OH und DMA geht DMAes Antibodies ? ) or Proteins= ( H )|. n = .1 - .20 DrugNHNH Drug pH 4 - 5 N NA se non presente trabalhando H Jn =come 1 ~ 20 EDC I UN DMA 0 0 Fig. 16 . Patent Application Publication May 2 , 2019 Sheet 12 of 22 US 2019 / 0127401 A1 0 H; ??? » NHNH 0 jH DMA NHS / EDC /DMA ??? ?? ? ?????????? ???? HCI/ Dioxane NHNH CNHNH, fyrir 100 ok noggly 6Hen ??? Drug Ri DrugN pH 4 5 OH R = H , Me, Et, orPh , .. »mAb + TCEP– ??????????? ?? ? : ?? ? mAb - - SH E yv42 0H n ? = 1? 20 ???????????? ??? ?????104 ?? ? - Fig . 17. Patent Application Publication May 2 , 2019 Sheet 13 of 22 US 2019 / 0127401 A1 an a word ener en en ?? ?? 1N NaOH O OEt - Na2CO3/ DMF OEt 105 106 OH NHS / EDC 0 . Antibodies or Proteins DMA OH 10107 ° DrugNHNH , H | n = 1 - 20 pH 4 - 5 Roman 108 to urdu N Hjn = 1 - 20 gourmalin hom op grond van het leven en hoe NHS /EDC DrugN DMA are not tomention Fig . 18 . Patent Application Publication May 2 , 2019 Sheet 14 of 22 US 2019 / 0127401 A1 HMDS OSIMez 1 Br ( 6 eq ) H - P - H Br Br CH (OEt ) ; O?NH + 120°C , 2h ! OSIM 120 °C , 5h ?? 140 °C 0 0 E1CNH( 0 . 8 eq ) O / NaCO3 + Eto OEt . N3 . in 14 DMF, then NaN3, miten113 ei38 % from112ole personenEt Ó ' 115 1 ) . PPh3/ DME /HCI ( 1M ) , 85°C H2N Drug - -COOH 2 ) . Tol.
Load more

Recommended publications
  • Synthesis and Biological Evaluation of Trisindolyl-Cycloalkanes and Bis- Indolyl Naphthalene Small Molecules As Potent Antibacterial and Antifungal Agents
    Synthesis and Biological Evaluation of Trisindolyl-Cycloalkanes and Bis- Indolyl Naphthalene Small Molecules as Potent Antibacterial and Antifungal Agents Dissertation Zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) Vorgelegt der Naturwissenschaftlichen Fakultät I Institut für Pharmazie Fachbereich für Pharmazeutische Chemie der Martin-Luther-Universität Halle-Wittenberg von Kaveh Yasrebi Geboren am 09.14.1987 in Teheran/Iran (Islamische Republik) Gutachter: 1. Prof. Dr. Andreas Hilgeroth (Martin-Luther-Universität Halle-Wittenberg, Germany) 2. Prof. Dr. Sibel Süzen (Ankara Üniversitesi, Turkey) 3. Prof. Dr. Michael Lalk (Ernst-Moritz-Arndt-Universität Greifswald, Germany) Halle (Saale), den 21. Juli 2020 Selbstständigkeitserklärung Hiermit erkläre ich gemäß § 5 (2) b der Promotionsordnung der Naturwissenschaftlichen Fakultät I – Institut für Pharmazie der Martin-Luther-Universität Halle-Wittenberg, dass ich die vorliegende Arbeit selbstständig und ohne Benutzung anderer als der angegebenen Hilfsmittel und Quellen angefertigt habe. Alle Stellen, die wörtlich oder sinngemäß aus Veröffentlichungen entnommen sind, habe ich als solche kenntlich gemacht. Ich erkläre ferner, dass diese Arbeit in gleicher oder ähnlicher Form bisher keiner anderen Prüfbehörde zur Erlangung des Doktorgrades vorgelegt wurde. Halle (Saale), den 21. Juli 2020 Kaveh Yasrebi Acknowledgement This study was carried out from June 2015 to July 2017 in the Research Group of Drug Development and Analysis led by Prof. Dr. Andreas Hilgeroth at the Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg. I would like to thank all the people for their participation who supported my work in this way and helped me obtain good results. First of all, I would like to express my gratitude to Prof. Dr. Andreas Hilgeroth for providing me with opportunity to carry out my Ph.D.
    [Show full text]
  • And Ritonavir-Boosted HIV Protease Inhibitors
    16 February 2012 EMA/CHMP/117973/2012 EMEA/H/C/002332/II/0004 Questions and answers on drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitors The European Medicines Agency has recommended changes to the prescribing information for Victrelis (boceprevir), a medicine used to treat hepatitis C, after a drug interaction study identified interactions between Victrelis and medicines used to treat HIV called ritonavir-boosted HIV protease inhibitors. These interactions could potentially reduce the effectiveness of these medicines if used together in patients being treated for both hepatitis C and HIV. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the changes to ensure doctors are informed of these interactions while further data are awaited to assess the clinical impact of these drug interaction findings on these patients. What is Victrelis? Victrelis is a medicine used to treat long-term hepatitis C genotype 1 (a disease of the liver due to infection with the hepatitis C virus) in adults with compensated liver disease who have not been treated before or whose previous treatment has failed. Compensated liver disease is when the liver is damaged but is still able to work normally. Victrelis is given in combination with two other medicines, peginterferon alfa and ribavirin. The active substance in Victrelis, boceprevir, is a protease inhibitor which blocks an enzyme called HCV NS3 protease found on the hepatitis C genotype 1 virus. Victrelis was authorised in the EU in July 2011. What is the issue with Victrelis? In January 2012, the EMA was informed of the results of a study in healthy volunteers which identified drug interactions between Victrelis and the antiviral medicines atazanavir, darunavir and lopinavir, which are used to treat HIV.
    [Show full text]
  • Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
    27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references .................................................................................................................................
    [Show full text]
  • HIV-Infected Patients
    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
    [Show full text]
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Review CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection
    Antiviral Chemistry & Chemotherapy 16:339–354 Review CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection Mike Westby* and Elna van der Ryst Pfizer Global R&D, Kent, UK *Corresponding author: Tel: +44 1304 649876; Fax: +44 1304 651819; E-mail: [email protected] The human chemokine receptors, CCR5 and suggest that these compounds have a long plasma CXCR4, are potential host targets for exogenous, half-life and/or prolonged CCR5 occupancy, which small-molecule antagonists for the inhibition of may explain the delay in viral rebound observed HIV-1 infection. HIV-1 strains can be categorised by following compound withdrawal in short-term co-receptor tropism – their ability to utilise CCR5 monotherapy studies. A switch from CCR5 to (CCR5-tropic), CXCR4 (CXCR4-tropic) or both (dual- CXCR4 tropism occurs spontaneously in approxi- tropic) as a co-receptor for entry into susceptible mately 50% of HIV-infected patients and has been cells. CCR5 may be the more suitable co-receptor associated with, but is not required for, disease target for small-molecule antagonists because a progression. The possibility of a co-receptor natural deletion in the CCR5 gene preventing its tropism switch occurring under selection pressure expression on the cell surface is not associated by CCR5 antagonists is discussed. The completion with any obvious phenotype, but can confer of ongoing Phase IIb/III studies of maraviroc, resistance to infection by CCR5-tropic strains – the aplaviroc and vicriviroc will provide further insight most frequently sexually-transmitted strains. into co-receptor tropism, HIV pathogenesis and The current leading CCR5 antagonists in clinical the suitability of CCR5 antagonists as a potent development include maraviroc (UK-427,857, new class of antivirals for the treatment of HIV Pfizer), aplaviroc (873140, GlaxoSmithKline) and infection.
    [Show full text]
  • Ep 2531027 B1
    (19) TZZ ¥_Z _T (11) EP 2 531 027 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4985 (2006.01) A61K 31/52 (2006.01) 06.05.2015 Bulletin 2015/19 A61K 31/536 (2006.01) A61K 31/513 (2006.01) A61K 38/55 (2006.01) A61P 31/18 (2006.01) (21) Application number: 11737484.3 (86) International application number: (22) Date of filing: 24.01.2011 PCT/US2011/022219 (87) International publication number: WO 2011/094150 (04.08.2011 Gazette 2011/31) (54) Therapeutic combination comprising dolutegravir, abacavir and lamivudine Therapeutische Zusammensetzung enthaltend Dolutegravir, Abacavir und Lamivudine Combinaison thérapeutique comprenant du dolutégravir, de l’abacavir et de la lamivudine (84) Designated Contracting States: (74) Representative: Gladwin, Amanda Rachel AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GlaxoSmithKline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Global Patents (CN925.1) PL PT RO RS SE SI SK SM TR 980 Great West Road Designated Extension States: Brentford, Middlesex TW8 9GS (GB) BA ME (56) References cited: (30) Priority: 27.01.2010 US 298589 P WO-A1-2010/011812 WO-A2-2009/148600 US-A1- 2006 084 627 US-A1- 2006 084 627 (43) Date of publication of application: US-A1- 2008 076 738 US-A1- 2009 318 421 12.12.2012 Bulletin 2012/50 US-A1- 2009 318 421 US-B1- 6 544 961 (73) Proprietor: VIIV Healthcare Company • SONG1 et al: "The Effect of Ritonavir-Boosted Research Triangle Park, NC 27709 (US) ProteaseInhibitors on the HIV Integrase Inhibitor, S/GSK1349572,in Healthy Subjects", INTERNET , (72) Inventor: UNDERWOOD, Mark, Richard 15 September 2009 (2009-09-15), XP002697436, Research Triangle Park Retrieved from the Internet: URL:http: North Carolina 27709 (US) //www.natap.org/2009/ICCAC/ICCAC_ 52.htm [retrieved on 2013-05-21] Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Humanization and Directed Evolution of the Selenium-Containing Scfv
    RSC Advances View Article Online PAPER View Journal | View Issue Humanization and directed evolution of the selenium-containing scFv phage abzyme Cite this: RSC Adv.,2018,8,17218 Yan Xu,a Pengju Li,a Jiaojiao Nie,a Qi Zhao, b Shanshan Guan,a Ziyu Kuai,a Yongbo Qiao,a Xiaoyu Jiang,a Ying Li,a Wei Li,a Yuhua Shi,a Wei Kongac and Yaming Shan *ac According to the binding site structure and the catalytic mechanism of the native glutathione peroxidase (GPX), three glutathione derivatives, GSH-S-DNP butyl ester (hapten Be), GSH-S-DNP hexyl ester (hapten He) and GSH-S-DNP hexamethylene ester (hapten Hme) were synthesized. By a four-round panning with a human synthetic scFv phage library against three haptens, the enrichment of the scFv phage particles with specific binding activity could be determined. Three phage particles were selected binding to each glutathione derivative, respectively. After a two-step chemical mutation to convert the serine residues of the scFv phage particles into selenocysteine residues, GPX activity could be observed and determined upto 3000 U mmolÀ1 in the selenium-containing scFv phage abzyme which was isolated by Creative Commons Attribution 3.0 Unported Licence. affinity capture against the hapten Be. Also the scFv phage abzymes elicited by different antigens displayed different catalytic activities. After a directed evolution by DNA shuffling to improve the affinity Received 31st March 2018 to the hapten Be, a secondary library with GPX activity was created in which the catalytic activity of the Accepted 3rd May 2018 selenium-containing scFv phage abzyme could be increased 17%.
    [Show full text]
  • Patient Resource Free
    PATIENT RESOURCE FREE Third Edition CancerUnderstanding Immunotherapy Published in partnership with CONTENT REVIEWED BY A DISTINGUISHED PRP MEDICAL PATIENT ADVISORY RESOURCE BOARD PUBLISHING® Understanding TABLE OF CONTENTS Cancer Immunotherapy Third Edition IN THIS GUIDE 1 Immunotherapy Today 2 The Immune System 4 Immunotherapy Strategies 6 Melanoma Survivor Story: Jane McNee Chief Executive Officer Mark A. Uhlig I didn’t look sick, so I didn’t want to act sick. Publisher Linette Atwood Having and treating cancer is only one part of your life. Co-Editor-in-Chief Charles M. Balch, MD, FACS Jane McNee, melanoma survivor Co-Editor-in-Chief Howard L. Kaufman, MD, FACS Senior Vice President Debby Easum 7 The Road to Immunotherapy Vice President, Operations Leann Sandifar 8 Cancer Types Managing Editor Lori Alexander, MTPW, ELS, MWC™ 14 Side Effects Senior Editors Dana Campbell Colleen Scherer 15 Glossary Graphic Designer Michael St. George 16 About Clinical Trials Medical Illustrator Todd Smith 16 Cancer Immunotherapy Clinical Trials by Disease Production Manager Jennifer Hiltunen 35 Support & Financial Resources Vice Presidents, Amy Galey Business Development Kathy Hungerford 37 Notes Stephanie Myers Kenney Account Executive Melissa Amaya Office Address 8455 Lenexa Drive CO-EDITORS-IN-CHIEF Overland Park, KS 66214 For Additional Information [email protected] Charles M. Balch, MD, FACS Advisory Board Visit our website at Professor of Surgery, The University of Texas PatientResource.com to read bios of MD Anderson Cancer Center our Medical and Patient Advisory Board. Editor-in-Chief, Patient Resource LLC Editor-in-Chief, Annals of Surgical Oncology Past President, Society of Surgical Oncology For Additional Copies: To order additional copies of Patient Resource Cancer Guide: Understanding Cancer Immunotherapy, Howard L.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Aplaviroc (APL, 873140)
    Hepatotoxicity observed in clinical trials of aplaviroc (APL, 873140) WG Nichols1, HM Steel1, TM Bonny1, SS Min1, L Curtis1, K Kabeya2, N Clumeck2 1 GlaxoSmithKline, Research Triangle Park, USA; 2 CHU-Saint-Pierre, Brussels, Belgium. Aplaviroc (APL, 873140, Ono 4128) O CH3 O HO • Specific CCR5 antagonist O N OH N NH • Potent HIV entry inhibitor O – mean 1.66 log10 decline at nadir in HIV-RNA after 10d monotherapy1 • Safety profile supported further study in humans 1 Lalezari J et al. AIDS 2005;19:1443–1448. Aplaviroc Phase 2b Program CCR100136 CCR102881 • 195 treatment-naïve • 147 treatment-naïve subjects randomized to subjects randomized to – APL 200mg BID / LPV/r – APL 600mg BID / Combivir – APL 400mg BID / LPV/r – APL 800mg BID / Combivir – APL 800mg QD / LPV/r – Combivir / efavirenz – LPV/r / Combivir – 2:2:1 randomisation – 2:2:2:1 randomization Sentinel case: Severe hepatitis • 39 year old HIV+ male – CD4 283 cells/mm3 – HBV/HCV negative – Normal AST/ALT/bilirubin • APL 800mg BID + COM • Day 59: developed severe hepatic cytolysis • Liver biopsy: – Chronic inflammatory infiltrate, mod intensity Liver biopsy (portal area) – Consistent with drug-induced hepatotoxicity CCR102881 Individual Patient LFT Plots ALP ALT AST BILT CK 70 60 50 40 30 APL RX 20 LFT Values (x ULN) 10 0 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 Study Day Review of Liver Enzyme Elevations in APL Phase IIb trials • 336 subjects received treatment – 282 subjects on APL – median duration of therapy: 13 wks • Central Lab database query to identify – any Grade
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew Et Al
    US 2016.0058872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0058872 A1 Crew et al. (43) Pub. Date: Mar. 3, 2016 (54) IMIDE-BASED MODULATORS OF A613 L/426 (2006.01) PROTEOLYSIS AND ASSOCATED METHODS A 6LX3 L/505 (2006.01) OF USE A613 L/454 (2006.01) A613 L/55 (2006.01) (71) Applicant: Arvinas, Inc., New Haven, CT (US) C07D40 L/4 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Andrew P. Crew, Guilford, CT (US); (52) U.S. Cl. Craig Crews, New Haven, CT (US), CPC ............ A61K 47/481 (2013.01); C07D401/14 Hanging Dong, Madison, CT (US); Jing (2013.01); C07D 495/14 (2013.01); C07D Wang, Milford, CT (US); Yimin Qian, 417/14 (2013.01); A61K 45/06 (2013.01); Plainsboro, NJ (US); Kam Siu Milford, A6 IK3I/505 (2013.01); A61 K3I/454 CT (US); Meizhong Jin, East Northport, (2013.01); A61 K3I/551 (2013.01); A61 K NY (US) 3 1/426 (2013.01) (21) Appl. No.: 14/792,414 (57) ABSTRACT (22) Filed: Jul. 6, 2015 The description relates to imide-based compounds, including Related U.S. Application Data bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially (63) Continuation-in-part of application No. 14/686.640, inhibitors of a variety of polypeptides and other proteins filed on Apr. 14, 2015. which are degraded and/or otherwise inhibited by bifunc (60) Provisional application No. 61/979,351, filed on Apr. tional compounds according to the present invention. In par 14, 2014, provisional application No.
    [Show full text]